VWM
CRBP icon

Venturi Wealth Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Venturi Wealth Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-317
Closed -$3.74K – 837
2024
Q4 		$3.74K Buy
317
+228
+256% +$3.82K ﹤0.01% 1773
2024
Q3 		$1.84K Buy
+89
New +$4.55K ﹤0.01% 1679

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Venturi Wealth Management's CRBP Position: Q1 2025 in Review

Venturi Wealth Management sold out of Corbus Pharmaceuticals (CRBP) in Q1 2025, closing a stake of 317 shares — an estimated $3.74K sold.

Venturi Wealth Management first reported a position in CRBP in Q3 2024 and held it in 2 quarters. The position peaked at $3.74K in Q4 2024. 86 funds tracked by Wall St. Rank hold CRBP as of Q1 2025.

  • Venturi Wealth Management reported no remaining Corbus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Venturi Wealth Management sold 317 Corbus Pharmaceuticals shares in Q1 2025, an estimated $3.74K.
  • Venturi Wealth Management first reported a position in Corbus Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Venturi Wealth Management's Corbus Pharmaceuticals position peaked at $3.74K in Q4 2024.
  • 86 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2025.

Based on Venturi Wealth Management's 13F filing for Q1 2025, filed 6 May 2025.